The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.” TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

JUNE 9, 2025

The acceptance, which follows the CDE’s grant of Priority Review status in May, represents an accelerated regulatory pathway for what may become the first approved systemic therapy for TGCT in China. Pimicotinib: A Promising CSF-1R Inhibitor Pimicotinib is an investigational small molecule developed by Abbisko Therapeutics Co.,

Treatment 40

Treatment Therapies Small Molecule Marketing 40

Conversations in Drug Development Trends

APRIL 4, 2024

To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

New Drug Approvals

MAY 26, 2025

M in tetrahydrofuran) was added at room temperature at a rate to maintain the internal temperature below 30 C. Ervogastat CAS 2186700-33-2 Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK – U.S.) 1] Its development was previously halted by the company but resumed in 2022. [2] equiv) in tetrahydrofuran (1.3

Small Molecule 62

Small Molecule Production Trials Drugs 62

The Premier Consulting Blog

NOVEMBER 20, 2024

For drugs with FDA Orphan Drug Designation (ODD), Breakthrough Therapy Designation (BTD), and EMA PRIority MEdicines designation (PRIME), all clinical, non-clinical, and CMC requirements are still required for regulatory approval, despite being on pathways for an expedited approval process.

Small Molecule 52

Small Molecule Drugs FDA Production 52

New Drug Approvals

APRIL 2, 2025

1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 The application received Breakthrough Therapy , Fast Track and Priority Review designations by the FDA. 11] The FDA granted the application for suzetrigine priority review , fast track , and breakthrough therapy designations. [2]

FDA 62

FDA Therapies Trials Treatment 62

LifeSciVC

APRIL 24, 2024

and whether a molecule’s pharmacology can help to mitigate safety risk. Especially for oligo or small molecule discovery and development, it’s important to understand whether there are highly homologous sequences or proteins that may be impacted by a given therapeutic approach. in liver, in CNS)?

Production 133

Production Small Molecule Regulations Trials 133

LifeSciVC

APRIL 2, 2024

And the experience of those around you, including Board members and internal investors. We are confident that there is room for improvement over existing cystic fibrosis (CF) therapies because we have not yet achieved fully normalized function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Science 83

Science Small Molecule International Clinical Development 83

The Pharma Data

JANUARY 31, 2021

Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?, or its ability to internalize PSMA.

Small Molecule 40

Small Molecule FDA Approval Trials Therapies 40

The Pharma Data

OCTOBER 6, 2021

The companies do not expect the introduction of booster doses in the United States and the EU, if authorized, to impact the existing supply agreements in place with governments and international health organizations around the world. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC and TTM Capital.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JANUARY 19, 2021

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

New Drug Approvals

APRIL 18, 2025

Compound 8A was previously described in International Publication Number WO2010/125414 by Sanofi-Aventis.Example 1: Preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1), See FIG. New Drug Therapy Approvals 2024 (PDF).

FDA 62

FDA FDA Approval Drugs Trials 62

The Pharma Data

NOVEMBER 18, 2020

Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. .” Presentation number: 397P / Poster: ID 680. Presenter: Ching-Liang Ho MD, et.al. Session Title: E-poster Display session – Thoracic tumours, metastatic.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Rare diseases is a high-growth therapy area with rapid innovation and significant unmet medical need. UK : +44 203 481 5237.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

The Pharma Data

OCTOBER 18, 2020

Dr. Berk most recently has served as a consultant to several companies developing oncology therapies. Dr. Berk completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology at the Weill Cornell Medical College and New York Presbyterian Hospital, where he also served as a faculty member.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

MARCH 1, 2022

“There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases,” said Tom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. “I am delighted with the closing of this deal.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

MAY 16, 2022

About Digestive Disease Week® Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Disease 40

Disease Small Molecule Treatment Trials 40

The Pharma Data

DECEMBER 15, 2020

The clinical responses were sustained by maintenance therapy with belimumab, an antibody to B-cell activating factor. Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. Oral, Small Molecules.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Drug Target Review

NOVEMBER 22, 2023

Whilst TGF-β is an attractive target for cancer therapy because of its critical role in promoting tumor aggressiveness, immune escape and resistance to therapy, activation of alternative resistance pathways has hindered drug development attempts in the past.

Licensing 52

Licensing Licensing Small Molecule Therapies 52

New Drug Approvals

JANUARY 31, 2024

PATENT The free base and salts of the compound of formula (I) may be prepared for example, according to the procedures given in International Patent Application No. It works as a colony-stimulating factor 1 ( CSF1 ) receptor inhibitor. [1] PCT/US2007/066898 filed on Apr. 18, 2007 and published as WO2007/121484 on Oct.

Small Molecule 52

Small Molecule Virus Treatment Disease 52

The Pharma Data

JANUARY 3, 2021

Sixty-two percent of patients were treated with prior PD(L)-1 containing therapy, and the arms were well balanced. Alternatively, the call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4787 (international) and referring to conference ID 5824089. SOUTH SAN FRANCISCO, Calif., Median PFS was 9.2 Exelixis, Inc.

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

The Pharma Data

JULY 15, 2021

Vincent’s Institute of Medical Research (SVI)’s multi-year research collaboration with Janssen Pharmaceuticals, Inc. Vincent’s Institute of Medical Research (SVI)’s multi-year research collaboration with Janssen Pharmaceuticals, Inc.

Government 52

Government Science Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

OCTOBER 18, 2020

Separate from the AML trial, Aptose is conducting a Phase 1 a/b dose escalation study with CG-806 in patients with B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphomas (NHL), who have failed or are intolerant to current therapies. About CG-806.

Small Molecule 40

Small Molecule Clinical Trials Trials Therapies 40

KIF1A

MAY 31, 2024

Trail Blazing in Australia International KAND Speech Study Our new research network partners at the Translation Centre for Speech Disorders in Australia welcomed families to take part in a study on speech and nonverbal communication in KIF1A Associated Neurological Disorder (KAND). You can read about her journey and first dose in our blog.

Treatment 52

Treatment Small Molecule International Research 52

The Pharma Data

DECEMBER 14, 2020

The effectiveness of standard therapy with TMZ is limited because the response of GBM to TMZ is dependent upon the expression of the DNA repair enzymatic protein, O 6 -alkylguanine DNA alkyltransferase (MGMT). At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist. Contact.

Clinical Trials 52

Clinical Trials DNA Drugs Therapies 52

The Pharma Data

JANUARY 7, 2021

As CEO of Freeline, a liver-directed gene therapy company, she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform.

Small Molecule 40

Small Molecule Clinical Development Production Science 40

Vial

FEBRUARY 19, 2024

Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. Can you elaborate on how the platform allows your company to tailor therapy? Ahmed Hamdy: Absolutely.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

The Pharma Data

DECEMBER 13, 2020

RLY-1971 has the potential to serve as a backbone for combination therapy across numerous solid tumors and therefore represents an encouraging approach for cancer patients,” said Sanjiv Patel, M.D., To access the live call, please dial 1 (833) 540-1168 (domestic) or 1 (929) 517-0359 (international) and refer to conference ID 8792127.

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

Codon

JUNE 11, 2024

Deamer chose this particular protein after reading papers that indicated that the ɑ-hemolysin protein has an internal diameter of 1-2 nanometers and was therefore large enough for nucleotides to pass through. These sequences can consist of words, audio, or, in the case of nanopores, “squiggles” in an electrical current.

DNA 99

DNA Engineering RNA Small Molecule 99

KIF1A

JUNE 30, 2023

This program helped obtain wheelchairs for 2 KAND patients and a vibration therapy plate to help one patient with their circulation. With these models established, we are preparing to test our first batch of small molecules drugs later this year! It also happens to be International Superhero Day.

Small Molecule 52

Small Molecule Treatment Doctors Research 52

The Pharma Data

FEBRUARY 18, 2022

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Vaccine 40

Vaccine Production Small Molecule Therapies 40

The Pharma Data

DECEMBER 15, 2020

NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. What makes this new therapy particularly exciting is the 5-day course of treatment and its good tolerability. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

New Drug Approvals

JANUARY 3, 2023

amcrasto@amcrasto ///////////////////////////////////////////////////////////////////////////// Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. 2] The FDA granted the application for adagrasib fast-track , breakthrough therapy , and orphan drug designations. [2] S2CID 226242453.

FDA 52

FDA Clinical Trials FDA Approval Treatment 52

The Anticancer Fund

JANUARY 12, 2022

The key finding is that women who receive progestin and metformin therapy have lower disease relapse than those receiving progestin alone. Combined therapy was not associated with significantly different remission rates or with different pregnancy and live birth rates.

Drugs 40

Drugs Clinical Trials Trials Small Molecule 40